Intraday Price Movement and Market Context
On 18 Mar 2026, Parmax Pharma opened at Rs.24.5, immediately reflecting a gap down of 11.71% from its previous close. The stock traded at this level throughout the day, touching an intraday low of Rs.24.5, which now stands as its lowest price point in the past year. This decline contrasts with the broader market’s modest gains, as the Sensex opened higher at 76,367.55, up 0.39%, and was trading at 76,342.59, a 0.36% increase at the time of reporting. Mega-cap stocks led the market rally, while Parmax Pharma notably underperformed its Pharmaceuticals & Biotechnology sector by 12.29% today.
Technically, Parmax Pharma is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend. The stock’s technical indicators further reinforce this downtrend, with weekly and monthly MACD, Bollinger Bands, and KST all showing bearish signals. The Dow Theory indicates no clear weekly trend and a mildly bearish monthly outlook, while the RSI remains neutral without a definitive signal.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Long-Term Performance and Financial Health
Over the past year, Parmax Pharma has delivered a total return of -45.18%, significantly underperforming the Sensex, which posted a positive return of 1.46% during the same period. The stock’s 52-week high was Rs.55.02, highlighting the extent of its decline to the current low. The company’s long-term fundamentals remain under pressure, reflected in its negative book value and a weak long-term fundamental strength assessment.
Financially, the company has experienced a contraction in net sales, with an annualised decline of 10.08% over the last five years. Operating profit growth has been modest at 6.65% annually during the same period. The latest six-month financials reveal a sharp downturn, with net sales falling by 55.91% to Rs.6.86 crores and a corresponding net loss (PAT) of Rs.-2.81 crores, also down by 55.91%. The company’s ability to service debt remains constrained, as indicated by a poor EBIT to interest ratio averaging 0.66, signalling limited coverage of interest expenses by operating earnings.
Profitability and Valuation Concerns
Parmax Pharma’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) have been negative, contributing to the stock’s classification as risky relative to its historical valuation averages. Profitability has deteriorated markedly, with profits falling by 94.6% over the past year. This decline in earnings, coupled with the stock’s negative returns, has resulted in a downgrade of its Mojo Grade from Sell to Strong Sell as of 16 Jun 2025, with a current Mojo Score of 3.0.
The stock’s underperformance extends beyond the last year, as it has lagged the BSE500 index over the last three years, one year, and three months, underscoring persistent challenges in both near-term and long-term performance metrics.
Shareholding Pattern and Market Position
The majority of Parmax Pharma’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company’s micro-cap status further emphasises its relatively small market capitalisation and the associated volatility risks.
Holding Parmax Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Technical Indicators
Technical analysis of Parmax Pharma reveals a predominantly bearish outlook. Weekly and monthly MACD indicators are bearish, as are Bollinger Bands on both timeframes. The daily moving averages confirm the downward momentum, with the stock trading below all major averages. The KST indicator also signals bearishness on weekly and monthly charts. The Dow Theory presents a mildly bearish monthly trend, though weekly trends remain inconclusive. The Relative Strength Index (RSI) does not currently provide a clear signal, indicating a lack of momentum either way.
Market Environment and Comparative Performance
While Parmax Pharma has struggled, the broader market environment has shown some resilience. The Sensex’s current position below its 50-day moving average, which itself is below the 200-day moving average, suggests a cautious market stance. However, mega-cap stocks have been leading the gains, contrasting with the micro-cap pharmaceutical stock’s continued decline. This divergence highlights the challenges faced by smaller companies in the sector amid prevailing market conditions.
Conclusion
Parmax Pharma Ltd’s fall to Rs.24.5, its 52-week low, reflects a combination of subdued financial performance, weak profitability, and persistent technical downtrends. The company’s negative book value, declining sales, and earnings contraction have contributed to its current market position. Despite a broader market rally led by mega-cap stocks, Parmax Pharma remains under pressure, with its stock price reflecting ongoing challenges in both fundamental and technical dimensions.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
